Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.

Autor: Ebenbichler C; Department of Internal Medicine I, Medical University Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria. Christoph.Ebenbichler@i-med.ac.at., Drexel H; Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT) at Feldkirch Academic Teaching Hospital, Feldkirch, Austria., Hanusch U; Center for Clinical Studies, Dr. Hanusch GmbH, Vienna, Austria., Toplak H; Department of Internal Medicine, Medical University Graz, Graz, Austria., Dhalwani NN; Amgen Inc., Thousand Oaks, CA, USA., Bridges I; Amgen Ltd., Uxbridge, UK., Hoelzl R; Amgen GmbH, Vienna, Austria., Hemetsberger M; Hemetsberger medical services, Vienna, Austria., Ray KK; Imperial Centre for Cardiovascular Disease Prevention and Imperial Clinical Trials Unit, Imperial College London, London, UK.
Jazyk: angličtina
Zdroj: Wiener klinische Wochenschrift [Wien Klin Wochenschr] 2024 Feb; Vol. 136 (3-4), pp. 77-86. Date of Electronic Publication: 2023 Jul 31.
DOI: 10.1007/s00508-023-02245-w
Abstrakt: Background: This real-world study examined clinical characteristics and dyslipidemia management among patients initiating evolocumab across 12 European countries. Austrian data are reported.
Methods: Data of consenting adults were collected for ≤ 6 months prior to evolocumab initiation (baseline) and ≤ 30 months post-initiation. Patient characteristics, lipid lowering therapy (LLT, i.e. statin and/or ezetimibe) and lipid values were collected from medical records.
Results: In Austria, 363 patients were enrolled. At baseline, 52% of patients initiated evolocumab without background LLT; the median (Q1, Q3) initial low-density lipoprotein cholesterol (LDL-C) level was 142 (111, 187) mg/dL. Within 3 months of evolocumab treatment, median LDL‑C decreased by 59% to 58 (37, 91) mg/dL. This reduction was maintained over time, despite consistently infrequent use of background LLT. LDL-C < 55 mg/dL was attained by 65% of patients (76% with, 55% without background LLT). Evolocumab persistence was ≥ 90% at month 12 and month 30.
Conclusion: In Austria, patients were initiated on evolocumab at LDL‑C levels almost 3‑times higher than the guideline-recommended clinical goal (< 55 mg/dL). Persistence with evolocumab was very high. Evolocumab led to a rapid and sustained LDL‑C reduction with 65% attaining the LDL‑C goal. Patients using evolocumab in combination with statins and/or ezetimibe were more likely to attain their LDL‑C goal and thus decrease cardiovascular risk.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: